[News] Discover the April 2, 2025 interview with Karine Lignel on the Journal des Biotechs!
An opportunity to review OPM’s development strategy and the latest news linked to the submission of the protocol for its Phase 1b/2a REVERT clinical trial with OPM-101!
To find out more, click here
Webinaire 1 April 05.30pm (in french)
Discover the replay here !
Discover OPM’s posters!
UEG Week 2024:
Authors : L Peyrin-Biroulet, M.D., PhD IHU INFINY – CHRU de NANCY, France; B. Robin Pharm.D, J. Hoflack, PhD, P. Genne, PhD – Oncodesign Precision Medicine, Dijon, France
AACR 2024:
- “Unlocking the Potential of OPM-383: A Novel LRRK2 Inhibitor in Cancer Therapy”
Authors: Maria Eugenia Riveiro, Petra Blom, Kenji Shoji, Jan Hoflack
Oncodesign Precision Medicine S.A., Dijon, France - “OPM-116, a highly potent and specific PI3Kγ inhibitor to enhance antitumor immunity”
Authors: Kenji F. Shoji, Oleksandr Levenets, Petra Blom, Maria Eugenia Riveiro, Jan Hoflack
Oncodesign Precision Medicine S.A., Dijon, France
IBD 2024 :
- “Unveiling the strong safety profile and high target engagement of OPM-101, a first-in-class orally available RIPK2 Inhibitor, in healthy volunteers, a Phase 1 Clinical trial “
Authors: ROBIN Bruno, Pharm.D. – HOFLACK Jan, PhD. – GENNE Philippe, PhD.
Oncodesign Precision Medicine S.A., Dijon, France